Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

Assessment of PD-1 and PD-L1 expression can be predictive of immunotherapy response in lung cancer. Here the authors assess the clinical toxicity, safety and quality of non-invasive imaging of PD-1 and PD-L1 expression in 13 patients with advanced lung cancer prior to treatment with immunotherapy an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: A. N. Niemeijer, D. Leung, M. C. Huisman, I. Bahce, O. S. Hoekstra, G. A. M. S. van Dongen, R. Boellaard, S. Du, W. Hayes, R. Smith, A. D. Windhorst, N. H. Hendrikse, A. Poot, D. J. Vugts, E. Thunnissen, P. Morin, D. Lipovsek, D. J. Donnelly, S. J. Bonacorsi, L. M. Velasquez, T. D. de Gruijl, E. F. Smit, A. J. de Langen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/d775b429652c43478095f6b7bc6015c1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Assessment of PD-1 and PD-L1 expression can be predictive of immunotherapy response in lung cancer. Here the authors assess the clinical toxicity, safety and quality of non-invasive imaging of PD-1 and PD-L1 expression in 13 patients with advanced lung cancer prior to treatment with immunotherapy and show it correlates with response.

Ejemplares similares